A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine Yara Ruiz GarciaVéronique AbitbolLamine Soumahoro Review Open access 30 September 2021 Pages: 639 - 655
Correction to: A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine Yara Ruiz GarciaVéronique AbitbolLamine Soumahoro Correction Open access 27 November 2021 Pages: 657 - 659
Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa Ashlan J. Kunz CoyneAmer El GhaliMichael J. Rybak Review Open access 12 February 2022 Pages: 661 - 682
Carbapenem-resistant Acinetobacter baumannii: Colonization, Infection and Current Treatment Options Carmi BartalKenneth V. I. RolstonLior Nesher Review Open access 17 February 2022 Pages: 683 - 694
Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review Rajamanthrilage Kasun MadusankaHermali SilvaNadira D. Karunaweera Review Open access 22 February 2022 Pages: 695 - 711
Coccidioidomycosis: A Contemporary Review Nancy F. Crum Review Open access 01 March 2022 Pages: 713 - 742
A Dalbavancin Lock Solution Can Reduce Enterococcal Biofilms After Freezing Marta Díaz-NavarroRama HafianMaría Guembe Original Research Open access 16 January 2022 Pages: 743 - 755
GMMA Technology for the Development of Safe Vaccines: Meta-Analysis of Individual Patient Data to Assess the Safety Profile of Shigella sonnei 1790GAHB Vaccine in Healthy Adults, with Special Focus on Neutropenia Iris De RyckEleanna SarakinouAudino Podda Original Research Open access 03 February 2022 Pages: 757 - 770
Association of Thiamine Use with Outcomes in Patients with Sepsis and Alcohol Use Disorder: An Analysis of the MIMIC-III Database Chang HuTong WuJianguo Li Original Research Open access 15 February 2022 Pages: 771 - 786
Machine Learning-Based COVID-19 Patients Triage Algorithm Using Patient-Generated Health Data from Nationwide Multicenter Database Min Sue ParkHyeontae JoHyung Ju Hwang Original Research Open access 16 February 2022 Pages: 787 - 805
Efficacy and Safety of a Phytopharmaceutical Drug Derived from Cocculus hirsutus in Adults with Moderate COVID-19: a Phase 2, Open-label, Multicenter, Randomized Controlled Trial Sadhna JoglekarShivakumar S. IyerShashank R. Joshi Original Research Open access 18 February 2022 Pages: 807 - 826
Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study Matteo BassettiAntonio Venafrom the Study Group for Infections in Critically Ill Patients (ESGCIP) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Original Research Open access 19 February 2022 Pages: 827 - 840
Adverse Reactions in a Phase 1 Trial of the Anti-Malarial DM1157: An Example of Pharmacokinetic Modeling and Simulation Guiding Clinical Trial Decisions Stephen J. BalevicShruti M. RajaJeffrey T. Guptill Original Research Open access 20 February 2022 Pages: 841 - 852
Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies David L. PatersonMasahiro KinoshitaSimon Portsmouth Original Research Open access 20 February 2022 Pages: 853 - 870
Performance of Nucleic Acid Amplification Tests in Patients with Presumptive Pulmonary Tuberculosis in Taiwan Wei-Chang HuangChih-Bin LinChen-Yuan Chiang Original Research Open access 07 March 2022 Pages: 871 - 885
Impact of Early Corticosteroids on Preventing Clinical Deterioration in Non-critically Ill Patients Hospitalized with COVID-19: A Multi-hospital Cohort Study Lakshmi SwaminathanScott KaatzHallie C. Prescott Original Research Open access 10 March 2022 Pages: 887 - 898
EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT): Methodology and Baseline Characteristics of a Community-Based Surveillance Study Ryan D. KilpatrickOlga Sánchez-SoliñoGregory C. Gray Brief Report Open access 02 February 2022 Pages: 899 - 911
Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension Robert S. Brown Jr.Michelle A. CollinsJordan J. Feld Brief Report Open access 17 February 2022 Pages: 913 - 924
Letter to the Editor Regarding “Influence of Baseline Physical Activity as a Modifying Factor on COVID-19 Mortality: A Single-Center, Retrospective Study” Charles Phillipe de Lucena AlvesMarcelo Rodrigues dos SantosDaisy Motta-Santos Letter Open access 04 February 2022 Pages: 925 - 927
A Response to: Letter to the Editor Regarding “Influence of Baseline Physical Activity as a Modifying Factor on COVID-19 Mortality: A Single-Center, Retrospective Study” Ricardo Salgado-Aranda Letter Open access 02 February 2022 Pages: 929 - 931
Correction to: Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study María Martínez-RebollarLorena De La MoraMontserrat Laguno Correction Open access 16 February 2022 Pages: 933 - 933
Correction to: Ceftazidime-Avibactam in Combination with In Vitro Non-susceptible Antimicrobials Versus Ceftazidime-Avibactam in Monotherapy in Critically Ill Patients with Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective Cohort Study Guanhao ZhengJianxin ZhangXiaolan Bian Correction Open access 28 February 2022 Pages: 935 - 936